LASSEN THERAPEUTICS
Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The companyโs lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be more effective than targeting other factors such as TGF-ฮฒ and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.
LASSEN THERAPEUTICS
Industry:
Biotechnology Life Science
Founded:
2018-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.lassentherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(858) 251-7528
Email Addresses:
[email protected]
Total Funding:
31 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API WordPress Wordpress Plugins Nginx Sitelinks Search Box Microsoft Exchange Online
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Alta Partners
Alta Partners investment in Series A - Lassen Therapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Lassen Therapeutics
Longwood Fund
Longwood Fund investment in Series A - Lassen Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-18 | Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer |
Official Site Inspections
http://www.lassentherapeutics.com Semrush global rank: 8.08 M Semrush visits lastest month: 376
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Lassen Therapeutics"
Lassen Therapeutics - Crunchbase Company Profile
Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.See details»
Lassen Therapeutics - LinkedIn
Lassen Therapeutics Biotechnology Research San Diego, California 4,598 followers Combining innovative science, leading technology, and unmatched know-how to create novel medicines.See details»
Lassen Therapeutics Company Profile | Management and
Find contact information for Lassen Therapeutics. Learn about their Research & Development, Business Services market share, competitors, and Lassen Therapeutics's email format.See details»
Leadership - Lassen
Proven track record of building robust antibody development platforms and pipelinesSee details»
Lassen Therapeutics 2025 Company Profile: Valuation, โฆ
Information on valuation, funding, cap tables, investors, and executives for Lassen Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Lassen Therapeutics - Craft
Lassen Therapeutics is a company that develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. Its lead candidate is LASN01, a monoclonal antibody targeting IL โฆSee details»
Lassen Therapeutics Announces the Appointment of a Highly โฆ
Oct 7, 2021 IL-11 is also an important effector of tumor microenvironment organization, playing a key role as a mediator between cancer and stromal cells. For more information, please visit โฆSee details»
Lassen Therapeutics | VentureRadar
Lassen Therapeutics develops breakthrough antibodies as potential treatments for fibrosis, rare diseases, and oncology. The companyโs lead candidate is LASN01, a best-in-class โฆSee details»
Org Chart Lassen Therapeutics - The Official Board
The org chart of Lassen Therapeutics contains its 14 main executives including Maria Fardis, David King and Debra Harris.See details»
Overview, News & Similar companies - ZoomInfo.com
View Lassen Therapeutics (www.lassentherapeutics.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees โฆSee details»
Lassen Therapeutics - VentureRadar
IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than and additive to other anti-fibrotic therapeutic โฆSee details»
Lassen - Overview, News & Similar companies | ZoomInfo.com
View Lassen (www.lassentherapeutics.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and โฆSee details»
About - Lassen
© 2025 Lassen TherapeuticsSite CreditsSee details»
Lassen Therapeutics 1, Inc. - Drug pipelines, Patents ... - Patsnap
Mar 8, 2025 Explore Lassen Therapeutics 1, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Neoplasms, Immune System Diseases ...See details»
Lassen Therapeutics-Lassen Therapeutics 1, Inc.-ไผไธ่ฏฆๆ โฆ
IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells. For more information, please visit โฆSee details»
Our Approach - Lassen
Targeting mechanisms of action with the potential for high impact on disease biology Deploying best-in-class, best-suited technologies for maximal speed and efficiency Generating high โฆSee details»
Lassen Therapeutics Announces the Appointment of a Highly โฆ
Oct 7, 2021 IL-11 is also an important effector of tumor microenvironment organization, playing a key role as a mediator between cancer and stromal cells.See details»
Inside the futuristic biotech startup Cellares thatโs ... - Fortune
2 days ago The company has now raised $355 million in funding, and signed a $380 million deal last year to reserve manufacturing capacity for Bristol Myers Squibbโs cell therapy drugs. But โฆSee details»
Lassen Therapeutics Announces Formation of Scientific Advisory โฆ
Dec 15, 2020 IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells. For more โฆSee details»
Lassen Therapeutics Launches to Discover and Develop Novel โฆ
Jun 17, 2020 IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells. For more โฆSee details»